Stay updated on Nivolumab in Pediatric Hypermutant Cancers Clinical Trial

Sign up to get notified when there's something new on the Nivolumab in Pediatric Hypermutant Cancers Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab in Pediatric Hypermutant Cancers Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    Revision: v3.4.3 added and v3.4.2 removed; this reflects a site version update rather than changes to study information.
    Difference
    0.1%
    Check dated 2026-03-12T00:00:53.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    20 days ago
    No Change Detected
  4. Check
    34 days ago
    Change Detected
    Summary
    Revision: v3.4.2 is now displayed; the page shows the new revision and removes the earlier v3.4.1 notice. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-11T14:16:56.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    A site-wide notice about government funding status was added and the page revision updated from v3.4.0 to v3.4.1.
    Difference
    0.4%
    Check dated 2026-02-04T10:36:35.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    The update adds a 'Show glossary' option and a 'No FEAR Act Data' disclosure with a 'Revision: v3.4.0' note. It also includes a minor capitalization change to the 'Last Update Submitted' label.
    Difference
    0.2%
    Check dated 2026-01-28T06:21:00.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    The page revision label was updated to v3.3.4 and the previous v3.3.3 entry was removed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-14T02:20:26.000Z thumbnail image
  8. Check
    84 days ago
    Change Detected
    Summary
    Locations section updated with multiple sites across Massachusetts, Pennsylvania, New South Wales, Queensland, South Australia, British Columbia, and Ontario, and the revision label updated to v3.3.3. The HHS Vulnerability Disclosure link and several regional location entries were removed (Massachusetts, Pennsylvania, New South Wales, Queensland, South Australia, British Columbia, Ontario).
    Difference
    0.8%
    Check dated 2025-12-23T13:30:51.000Z thumbnail image

Stay in the know with updates to Nivolumab in Pediatric Hypermutant Cancers Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab in Pediatric Hypermutant Cancers Clinical Trial page.